Observational studyInternational journal of cancer2025
Performance of upper gastrointestinal endoscopy in CDH1 germline pathogenic variant carriers: A multicenter study.
Observational study in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges.International journal of cancer · 2026Review
- Risk factors and clinical outcomes associated with leptomeningeal carcinomatosis in gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- The Changing Landscape of Hereditary Diffuse Gastric Cancer.Journal of gastric cancer · 2026Review
- Performance of upper gastrointestinal endoscopy in CDH1 germline pathogenic variant carriers: A multicenter study.International journal of cancer · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Hereditary diffuse gastric cancer (HDGC) is a syndrome primarily caused by pathogenic variants in the CDH1 gene, characterized histologically by the presence of signet ring cell carcinoma (SRCC). This observational multicenter study aimed to characterize CDH1 carriers undergoing endoscopic surveillance at 12 Spanish centers, evaluate the performance of upper gastrointestinal endoscopy (UGE) in detecting SRCC, and identify factors associated with its diagnosis. Fifty-three CDH1 carriers who underwent at least one surveillance UGE were included. SRCC was detected in nine individuals (17%) through biopsies, including seven cases by random biopsies and two by targeted biopsies, all confirmed in subsequent gastrectomy specimens. Among 44 patients with negative endoscopic findings, 22 underwent risk-reducing gastrectomy, and SRCC was identified in 11 of these cases (50%) during pathological examination. Overall, SRCC was diagnosed in 20 individuals (37.7%), with UGE initially detecting 45% of cases. Only one case identified through targeted biopsies was found at an advanced stage (T4). Chromoendoscopy was associated with a higher detection rate of SRCC compared to conventional white light endoscopy (p = .017, odds ratio = 20 [95%CI, 1.68-238.63]). Despite current endoscopic practices, SRCC remained undetected in half of the patients undergoing risk-reducing gastrectomy. Future efforts should focus on enhancing endoscopic techniques and improving our understanding of the progression of these lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.